Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Zacks Research

Halozyme Therapeutics (NASDAQ:HALO) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Several other research firms have also recently weighed in on HALO. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $83.00 to $110.00 in a research report on Friday, August 7th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Finally, Wells Fargo & Company increased their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.50.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $116.82 on Tuesday. The business has a fifty day moving average price of $107.97 and a two-hundred day moving average price of $84.24. The stock has a market capitalization of $13.26 billion, a PE ratio of 34.87, a P/E/G ratio of 0.41 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $119.21.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts predict that Halozyme Therapeutics will post 8.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Matthew Posard sold 5,230 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the sale, the director directly owned 53,609 shares of the company’s stock, valued at $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. This trade represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock worth $13,538,046 in the last ninety days. 2.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HALO. Congress Asset Management Co. boosted its stake in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $214,504,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $196,540,000. Royal London Asset Management Ltd. raised its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after buying an additional 200,262 shares during the last quarter. Finally, Jupiter Topco LLC bought a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $105,570,000. 97.79% of the stock is owned by institutional investors.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analyst sentiment strengthened. Zacks Research upgraded Halozyme from “Hold” to “Strong Buy,” while TD Cowen raised its price target from $105 to $130 and reaffirmed a Buy rating. The new target implies additional upside from the current trading level. TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics
• Positive Sentiment: Roche’s Tecentriq Hybreza approval expanded a potential royalty opportunity. The FDA approval for a new stage III dMMR colon cancer indication broadens the commercial market for a Roche product using Halozyme’s drug-delivery technology. Strong clinical results could support future demand and royalty revenue. Halozyme gains as partner-drug approval, patent win, and bullish analyst call lift sentiment
• Positive Sentiment: A European patent ruling reduced competitive concerns. A Dutch court injunction blocking manufacture and sale of Merck’s Keytruda SC in several European markets supports Halozyme’s intellectual-property position and may protect the outlook for its subcutaneous drug-delivery platform. Halozyme gains as partner-drug approval, patent win, and bullish analyst call lift sentiment
• Positive Sentiment: Growth and earnings expectations remain supportive. Zacks highlighted Halozyme’s growth characteristics, while another report pointed to the company’s history of earnings surprises and potential for another beat in its next quarterly report.
• Neutral Sentiment: The stock is trading near its one-year high. Momentum is strong, with the shares well above their 50-day and 200-day moving averages, but the elevated valuation increases sensitivity to any earnings or guidance disappointment.
• Negative Sentiment: Insider selling is a risk signal. Quiver Quantitative reported 67 insider sales and no purchases over the past six months, including substantial sales by CEO Helen Torley. Institutional positioning was mixed, with some funds adding shares while others reduced or exited holdings. Halozyme gains as partner-drug approval, patent win, and bullish analyst call lift sentiment

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.